This novel classification of GLI1+/IFT20+ ccRCC patients should have an impact on clinical practice, not only in characterizing new subgroups of ccRCC patients, but also in offering new combinations of treatments that are much more effective and more specific for a specific group of ccRCC patients. Here, IFT20 is linked to nonpapillary renal cell carcinoma.